In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog

With an FDA decision expected in the second half of 2022, Novartis’ Cosentyx looks on track to become the next biologic agent in HS, a painful skin disease where only one biologic treatment, AbbVie’s off-patent Humira, is approved in the U.S.